Charles Hart, PhD

Title(s)Exec Dir, Catalyst Program, Innovation Ventures
SchoolChancellor/EVC/FAS
Address490 Illinois Street, #52J
San Francisco CA 94158
vCardDownload vCard
    Other Positions
    Title(s)Adjunct Professor, Pharmaceutical Chemistry


    Collapse Biography 
    Collapse Education and Training
    University of California, BerkeleyAB1977Cell Biology
    Stanford UniversityMS1980Developmental Biology
    Yale UniversityPhD1987Molecular Biology and Genetics
    Université de Strasbourg, FrancePostdoc1990Molecular Biology

    Collapse ORNG Applications 
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Retraction: Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy. Oncotarget. 2024 Feb 08; 15:123. Yoon C, Chang KK, Lee JH, Tap WD, Hart CP, Simon MC, Yoon SS. PMID: 38329733; PMCID: PMC10852056.
      View in: PubMed   Mentions:    Fields:    
    2. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. JCI Insight. 2023 02 22; 8(4). Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW. PMID: 36810255; PMCID: PMC9990753.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    3. Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide. Mol Pharmacol. 2019 06; 95(6):638-651. Hunter FW, Devaux JBL, Meng F, Hong CR, Khan A, Tsai P, Ketela TW, Sharma I, Kakadia PM, Marastoni S, Shalev Z, Hickey AJR, Print CG, Bohlander SK, Hart CP, Wouters BG, Wilson WR. PMID: 30979813.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    4. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. JCI Insight. 2018 08 23; 3(16). Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW. PMID: 30135316; PMCID: PMC6141174.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCellsCTClinical Trials
    5. Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study. Neuro Oncol. 2018 08 02; 20(9):1231-1239. Brenner A, Zuniga R, Sun JD, Floyd J, Hart CP, Kroll S, Fichtel L, Cavazos D, Caflisch L, Gruslova A, Huang S, Liu Y, Lodi A, Tiziani S. PMID: 29415215; PMCID: PMC6071657.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    6. Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models. Transl Oncol. 2018 Aug; 11(4):911-919. Kumar S, Sun JD, Zhang L, Mokhtari RB, Wu B, Meng F, Liu Q, Bhupathi D, Wang Y, Yeger H, Hart C, Baruchel S. PMID: 29803017; PMCID: PMC6041570.
      View in: PubMed   Mentions: 10  
    7. Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice. Cancer Res. 2018 07 15; 78(14):3783-3792. Matsumoto S, Kishimoto S, Saito K, Takakusagi Y, Munasinghe JP, Devasahayam N, Hart CP, Gillies RJ, Mitchell JB, Krishna MC. PMID: 29792309; PMCID: PMC8092078.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    8. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies. Antioxid Redox Signal. 2018 Jan 10; 28(2):131-140. Takakusagi Y, Kishimoto S, Naz S, Matsumoto S, Saito K, Hart CP, Mitchell JB, Krishna MC. PMID: 28741367; PMCID: PMC5725636.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    9. A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model. Transl Oncol. 2017 Oct; 10(5):760-765. Hajj C, Russell J, Hart CP, Goodman KA, Lowery MA, Haimovitz-Friedman A, Deasy JO, Humm JL. PMID: 28778024; PMCID: PMC5538966.
      View in: PubMed   Mentions: 21  
    10. Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models. Tomography. 2016 Sep; 2(3):229-237. Stokes AM, Hart CP, Quarles CC. PMID: 27752544; PMCID: PMC5065246.
      View in: PubMed   Mentions: 15     Fields:    
    11. Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer. Clin Cancer Res. 2017 Jan 15; 23(2):536-548. Duran R, Mirpour S, Pekurovsky V, Ganapathy-Kanniappan S, Brayton CF, Cornish TC, Gorodetski B, Reyes J, Chapiro J, Schernthaner RE, Frangakis C, Lin M, Sun JD, Hart CP, Geschwind JF. PMID: 27440271; PMCID: PMC5241187.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    12. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy. Oncotarget. 2016 Jul 12; 7(28):42844-42858. Yoon C, Chang KK, Lee JH, Tap WD, Hart CP, Simon MC, Yoon SS. PMID: 27374091; PMCID: PMC5189991.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    13. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS One. 2016; 11(5):e0155289. Zhang X, Wojtkowiak JW, Martinez GV, Cornnell HH, Hart CP, Baker AF, Gillies R. PMID: 27227903; PMCID: PMC4882075.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    14. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models. Cancer Biol Ther. 2016 04 02; 17(4):371-80. Sun JD, Liu Q, Ahluwalia D, Ferraro DJ, Wang Y, Jung D, Matteucci MD, Hart CP. PMID: 26818215; PMCID: PMC5036787.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    15. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models. Clin Cancer Res. 2016 Apr 01; 22(7):1687-98. Benito J, Ramirez MS, Millward NZ, Velez J, Harutyunyan KG, Lu H, Shi YX, Matre P, Jacamo R, Ma H, Konoplev S, McQueen T, Volgin A, Protopopova M, Mu H, Lee J, Bhattacharya PK, Marszalek JR, Davis RE, Bankson JA, Cortes JE, Hart CP, Andreeff M, Konopleva M. PMID: 26603259; PMCID: PMC4818660.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    16. Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models. Am J Cancer Res. 2015; 5(7):2139-55. Sun JD, Ahluwalia D, Liu Q, Li W, Wang Y, Meng F, Bhupathi D, Matteucci MD, Hart CP. PMID: 26328245; PMCID: PMC4548326.
      View in: PubMed   Mentions: 16  
    17. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer. 2015 May 21; 15:422. Meng F, Bhupathi D, Sun JD, Liu Q, Ahluwalia D, Wang Y, Matteucci MD, Hart CP. PMID: 25994202; PMCID: PMC4453293.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    18. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging. Clin Cancer Res. 2015 Jul 01; 21(13):2984-92. Peeters SG, Zegers CM, Biemans R, Lieuwes NG, van Stiphout RG, Yaromina A, Sun JD, Hart CP, Windhorst AD, van Elmpt W, Dubois LJ, Lambin P. PMID: 25805800.
      View in: PubMed   Mentions: 50     Fields:    Translation:Animals
    19. Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302. Cancer Metab. 2015; 3(1):2. Wojtkowiak JW, Cornnell HC, Matsumoto S, Saito K, Takakusagi Y, Dutta P, Kim M, Zhang X, Leos R, Bailey KM, Martinez G, Lloyd MC, Weber C, Mitchell JB, Lynch RM, Baker AF, Gatenby RA, Rejniak KA, Hart C, Krishna MC, Gillies RJ. PMID: 25635223; PMCID: PMC4310189.
      View in: PubMed   Mentions: 40  
    20. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biol Ther. 2015; 16(3):438-49. Sun JD, Liu Q, Ahluwalia D, Li W, Meng F, Wang Y, Bhupathi D, Ruprell AS, Hart CP. PMID: 25679067; PMCID: PMC4623012.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    21. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer. PLoS One. 2014; 9(12):e113586. Bailey KM, Cornnell HH, Ibrahim-Hashim A, Wojtkowiak JW, Hart CP, Zhang X, Leos R, Martinez GV, Baker AF, Gillies RJ. PMID: 25532146; PMCID: PMC4273999.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    22. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302. PLoS One. 2014; 9(9):e107995. Takakusagi Y, Matsumoto S, Saito K, Matsuo M, Kishimoto S, Wojtkowiak JW, DeGraff W, Kesarwala AH, Choudhuri R, Devasahayam N, Subramanian S, Munasinghe JP, Gillies RJ, Mitchell JB, Hart CP, Krishna MC. PMID: 25254649; PMCID: PMC4177858.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    23. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models. Clin Cancer Res. 2013 Dec 01; 19(23):6506-19. Portwood S, Lal D, Hsu YC, Vargas R, Johnson MK, Wetzler M, Hart CP, Wang ES. PMID: 24088735.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    24. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. Mol Cancer Ther. 2013 Sep; 12(9):1763-73. Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, De Bryune E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K. PMID: 23832122.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    25. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012 Jun 14; 119(24):5782-94. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM. PMID: 22394600; PMCID: PMC3382938.
      View in: PubMed   Mentions: 176     Fields:    Translation:HumansAnimalsCells
    26. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol. 2012 Jun; 69(6):1487-98. Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP. PMID: 22382881; PMCID: PMC3985381.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimalsCells
    27. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res. 2012 Feb 01; 18(3):758-70. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP. PMID: 22184053.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansAnimalsCells
    28. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther. 2012 Mar; 11(3):740-51. Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, Maroz A, Anderson RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart CP. PMID: 22147748.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansAnimalsCells
    29. 14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment. J Med Chem. 2011 Mar 24; 54(6):1715-23. Duan JX, Cai X, Meng F, Sun JD, Liu Q, Jung D, Jiao H, Matteucci J, Jung B, Bhupathi D, Ahluwalia D, Huang H, Hart CP, Matteucci M. PMID: 21341674.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    30. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood. 2010 Sep 02; 116(9):1524-7. Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K. PMID: 20530289.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansAnimalsCells
    31. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem. 2008 Apr 24; 51(8):2412-20. Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, Hoffman RM, Ammons WS, Hart CP, Matteucci M. PMID: 18257544.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimalsCells
    32. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity. Cancer Chemother Pharmacol. 2008 May; 61(6):953-63. Meng F, Cai X, Duan J, Matteucci MG, Hart CP. PMID: 17639393.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    33. ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation. Anticancer Drugs. 2007 Apr; 18(4):435-45. Meng F, Nguyen XT, Cai X, Duan J, Matteucci M, Hart CP. PMID: 17351396.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    34. Finding the target after screening the phenotype. Drug Discov Today. 2005 Apr 01; 10(7):513-9. Hart CP. PMID: 15809197.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimals
    35. Selection of estrogen receptor beta- and thyroid hormone receptor beta-specific coactivator-mimetic peptides using recombinant peptide libraries. Mol Endocrinol. 2000 May; 14(5):605-22. Northrop JP, Nguyen D, Piplani S, Olivan SE, Kwan ST, Go NF, Hart CP, Schatz PJ. PMID: 10809226.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    36. Potent inhibitory ligands of the GRB2 SH2 domain from recombinant peptide libraries. Cell Signal. 1999 Jun; 11(6):453-64. Hart CP, Martin JE, Reed MA, Keval AA, Pustelnik MJ, Northrop JP, Patel DV, Grove JR. PMID: 10400318.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    37. Genetic recombination as a reporter for screening steroid receptor agonists and antagonists. Anal Biochem. 1998 Apr 10; 258(1):96-102. Dias JM, Go NF, Hart CP, Mattheakis LC. PMID: 9527854.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    38. Homeotic transformation of the occipital bones of the skull by ectopic expression of a homeobox gene. Nature. 1992 Oct 29; 359(6398):835-41. Lufkin T, Mark M, Hart CP, Dollé P, LeMeur M, Chambon P. PMID: 1359423.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimalsCells
    39. Genetic linkage analysis of the murine developmental mutant velvet coat (Ve) and the distal chromosome 15 developmental genes Hox-3.1, Rar-g, Wnt-1, and Krt-2. J Exp Zool. 1992 Aug 01; 263(1):83-95. Hart CP, Compton JG, Langley SH, Hunihan L, LeClair KP, Zelent A, Roderick TH, Ruddle FH. PMID: 1379621.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    40. The developmental expression pattern of a new murine homeo box gene: Hox-2.5. Dev Biol. 1989 Jun; 133(2):537-49. Bogarad LD, Utset MF, Awgulewitsch A, Miki T, Hart CP, Ruddle FH. PMID: 2567250.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    41. The Hox-2 homeo box gene complex on mouse chromosome 11 is closely linked to Re. Genetics. 1988 Feb; 118(2):319-27. Hart CP, Dalton DK, Nichols L, Hunihan L, Roderick TH, Langley SH, Taylor BA, Ruddle FH. PMID: 2896141; PMCID: PMC1203284.
      View in: PubMed   Mentions: 9     Fields:    Translation:Animals
    42. Sequence analysis of the murine Hox-2.2, -2.3, and -2.4 homeo boxes: evolutionary and structural comparisons. Genomics. 1987 Oct; 1(2):182-95. Hart CP, Fainsod A, Ruddle FH. PMID: 2891608.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    43. Polypurine/polypyrimidine sequence elements of the murine homeo box loci, Hox-1, -2 and -3. Nucleic Acids Res. 1987 Jul 10; 15(13):5495. Hart CP, Bogarad LD, Fainsod A, Ruddle FH. PMID: 2885806; PMCID: PMC305990.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    44. Homeo box genes in murine development. Curr Top Dev Biol. 1987; 23:233-56. Fienberg AA, Utset MF, Bogarad LD, Hart CP, Awgulewitsch A, Ferguson-Smith A, Fainsod A, Rabin M, Ruddle FH. PMID: 2897895.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    45. Cognate homeo-box loci mapped on homologous human and mouse chromosomes. Proc Natl Acad Sci U S A. 1986 Dec; 83(23):9104-8. Rabin M, Ferguson-Smith A, Hart CP, Ruddle FH. PMID: 2878432; PMCID: PMC387083.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    46. Spatial restriction in expression of a mouse homoeo box locus within the central nervous system. Nature. 1986 Mar 27-Apr 2; 320(6060):328-35. Awgulewitsch A, Utset MF, Hart CP, McGinnis W, Ruddle FH. PMID: 3007994.
      View in: PubMed   Mentions: 50     Fields:    Translation:AnimalsCells
    47. Homeo box gene complex on mouse chromosome 11: molecular cloning, expression in embryogenesis, and homology to a human homeo box locus. Cell. 1985 Nov; 43(1):9-18. Hart CP, Awgulewitsch A, Fainsod A, McGinnis W, Ruddle FH. PMID: 3000607.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    48. Two homoeo box loci mapped in evolutionarily related mouse and human chromosomes. Nature. 1985 Mar 14-20; 314(6007):175-8. Rabin M, Hart CP, Ferguson-Smith A, McGinnis W, Levine M, Ruddle FH. PMID: 4038785.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    49. Structural and functional aspects of the mammalian homeo box sequences. Trends in Genetics. 1985; 1(1):48-51. F.H. Ruddle, C.P. Hart and W. McGinnis. . View Publication.
    50. Mammalian homeo box genes. Cold Spring Harb Symp Quant Biol. 1985; 50:277-84. Ruddle FH, Hart CP, Awgulewitsch A, Fainsod A, Utset M, Dalton D, Kerk N, Rabin M, Ferguson-Smith A, Fienberg A, et al. PMID: 2420513.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    51. Molecular cloning and chromosome mapping of a mouse DNA sequence homologous to homeotic genes of Drosophila. Cell. 1984 Oct; 38(3):675-80. McGinnis W, Hart CP, Gehring WJ, Ruddle FH. PMID: 6091896.
      View in: PubMed   Mentions: 81     Fields:    Translation:AnimalsCells
    52. Molecular cloning and chromosome assignment of murine N-ras. Nucleic Acids Res. 1984 Aug 10; 12(15):6063-72. Ryan J, Hart CP, Ruddle FH. PMID: 6089108; PMCID: PMC320057.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    Charles's Networks
    Concepts (305)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (1)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.